Protalix BioTherapeutics (NYSE:PLX) Shares Up 3.4% - Still a Buy?

Protalix BioTherapeutics, Inc. (NYSE:PLX - Get Free Report)'s share price shot up 3.4% on Wednesday . The company traded as high as $1.53 and last traded at $1.53. 595,311 shares traded hands during mid-day trading, an increase of 2% from the average session volume of 585,289 shares. The stock had previously closed at $1.48.

Analysts Set New Price Targets

Separately, Wall Street Zen downgraded Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a research note on Monday, May 12th.

Protalix BioTherapeutics Stock Up 3.4%

The company has a market capitalization of $121.80 million, a price-to-earnings ratio of -11.77 and a beta of -0.23. The stock has a fifty day moving average price of $1.74 and a two-hundred day moving average price of $2.16.

Protalix BioTherapeutics (NYSE:PLX - Get Free Report) last released its earnings results on Friday, May 9th. The company reported ($0.05) EPS for the quarter. Protalix BioTherapeutics had a negative net margin of 21.03% and a negative return on equity of 30.89%. As a group, research analysts forecast that Protalix BioTherapeutics, Inc. will post 0.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Protalix BioTherapeutics

Several institutional investors and hedge funds have recently modified their holdings of PLX. NewEdge Advisors LLC purchased a new stake in shares of Protalix BioTherapeutics in the first quarter worth about $39,000. Cubist Systematic Strategies LLC boosted its holdings in Protalix BioTherapeutics by 24.1% in the fourth quarter. Cubist Systematic Strategies LLC now owns 29,307 shares of the company's stock valued at $55,000 after purchasing an additional 5,686 shares during the last quarter. Prudential Financial Inc. purchased a new position in Protalix BioTherapeutics in the fourth quarter valued at about $68,000. Point72 Asia Singapore Pte. Ltd. boosted its holdings in Protalix BioTherapeutics by 13.7% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 53,507 shares of the company's stock valued at $101,000 after purchasing an additional 6,434 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in Protalix BioTherapeutics in the first quarter valued at about $107,000. Hedge funds and other institutional investors own 16.53% of the company's stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.